Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) will present new data from the Phase 2 SOLSTICE trial in chronic hepatitis delta at the EASL Congress 2026 in Barcelona, May 27-30, 2026.
The Week 96 efficacy and safety results in hepatitis delta are featured in an oral “Best of EASL 2026” session, and a Week 48 BMI subgroup analysis is highlighted in an EASL poster tour.
Vir Biotechnology (Nasdaq: VIR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: a closed global collaboration with Astellas for VIR-5500 with first patient dosed; positive Phase 2 SOLSTICE CHD results (77% HDV RNA TND at Week 72; 88% at Week 96 subset); $809.3M cash and investments as of March 31, 2026; net loss of $125.7M in Q1; cash runway to the second half of 2028.
Additional notes: completed $172.5M follow-on offering; Phase 3 ECLIPSE topline expected Q4 2026; complete Week 96 SOLSTICE data to be presented at EASL May 27-30, 2026.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will appear in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas.
A live webcast will be available at the company's investor site and archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Wednesday, May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss financial results for the quarter ended March 31, 2026. The call is accessible via the company's Events & Presentations web page.
Vir Biotechnology (Nasdaq: VIR) closed its global collaboration and licensing agreement with Astellas on April 16, 2026, after the Hart-Scott-Rodino waiting period expired. The deal advances VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer.
Key financial terms: Vir received a $240 million upfront, a $75 million equity investment at $10.36/share, a near-term $20 million milestone, will split U.S. profit/loss 50/50, and is eligible for up to $1.37 billion in milestones plus tiered double-digit ex-U.S. royalties; certain proceeds will be shared with Sanofi.
Vir Biotechnology (Nasdaq: VIR) announced the first patient dosed in a Phase 1 dose-expansion cohort evaluating VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer (NCT05997615) on April 13, 2026.
The monotherapy expansion in late-line mCRPC will test a selected Q3W 800/2000/3500 µg/kg step-up dosing after Phase 1 dose-escalation data showed a favorable safety profile and promising anti-tumor activity presented at ASCO in February 2026. Combination expansion cohorts with an ARPI are expected to dose in the coming months ahead of planned pivotal Phase 3 trials in 2027.
Vir Biotechnology (Nasdaq: VIR) said management will participate in three investor conferences in March 2026: TD Cowen (fireside chat Mar 2, 3:10 p.m. ET), Leerink Partners (fireside chat Mar 10, 1:40 p.m. ET), and Barclays (one-on-one meetings Mar 12).
Live webcasts of the fireside chats will be available at the company investor website and archived for 30 days.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) announced a proposed underwritten public offering of $200,000,000 of common stock, with a 30-day underwriter option to purchase up to an additional $30,000,000 of shares. All shares will be offered by Vir and the offering is subject to market conditions and SEC filings.
Goldman Sachs, Leerink Partners, Evercore ISI and Barclays are book-running managers. The shares are being offered under an automatically effective Form S-3 registration filed November 3, 2023.
Vir Biotechnology (Nasdaq: VIR) reported Q4 and full-year 2025 results and provided a corporate update on Feb 23, 2026. Key developments include a global collaboration with Astellas for PSMA-targeted TCE VIR-5500, updated Phase 1 VIR-5500 data showing favorable safety and anti-tumor activity, and $781.6 million in cash and investments as of Dec 31, 2025.
Pipeline and commercial moves include a Norgine license for tobevibart+elebsiran in select regions and upcoming Phase 3 plans for VIR-5500 in 2027.